EAPA Lone Star

Digital Therapeutics

  • 16 Jun 2021
  • 11:30 AM - 1:00 PM
  • Virtual Meeting - Webinar


Global Digital Therapeutics Market influenced by technological innovations and arrangement described in a new report - WhaTech

Newest Trends in Digital Therapeutics 

About this Event

This is a virtual meeting.

FREE Registration is by invitation through Eventbrite.

Contact eapa.lonestar@gmail.com to get on our email list.


Depression, Problematic Drinking, Opioid Use Disorder, and the Role of Digital Therapeutics – Overview


Quentin O’Brien, MPH

Medical Science Liaison, Digital Therapeutics at Orexo US, Inc.

Session Educational Summary:

There is an evolution occurring in how digital technology is advancing and being used to support the delivery of mental and behavioral health care. The COVID-19 pandemic brought mental health and gaps in mental health care to the forefront in the areas of depression and substance use disorders. Digital therapeutics represent one potential tool that can be used to address these gaps in care. By the end of this session, participants will demonstrate an understanding of common mental health issues facing the American workforce and how digital therapeutics can help to address these issues. Orexo’s digital therapeutic deprexis® will provide a tangible example of just one mental health digital therapeutic.

Learning Objectives:

  • Participants will be able to demonstrate an understanding of depression, problematic drinking, and opioid use disorder, and how these mental health issues impact the workforce.
  • Participants will be able to describe digital therapeutics in the mental health space, and they will be able to use deprexis as an example of just one mental health digital therapeutic.
  • Participants will be able to assess the clinical data supporting the use of digital therapeutics with a particular focus on Orexo’s digital therapeutics deprexis® and vorvida®.

About our Speaker


Morristown, NJ | (973) 294–3531 | quentin.obrien@orexo.com | she/her/hers


George Washington University

Doctor of Philosophy (PhD), Translational Health Sciences

·       Dissertation: Exploring Client Satisfaction with Videoconferencing Psychotherapy Among Diverse Populations: A Mixed Methods Study

Washington, DC (remote)

Expected May 2022

Mailman School of Public Health, Columbia University

Master of Public Health (MPH)

New York, NY

May 2015

Rensselaer Polytechnic Institute (RPI)

Bachelor of Science (BS), Environmental Science, Concentration in Biology

Troy, NY

May 2013


Orexo US, Inc.

Medical Science Liaison, Digital Therapeutics

Morristown, NJ

May 2020 – Present

· Lead field-based medical activities for the digital therapeutics portfolio, which includes deprexis (for management of depression) and vorvida (for management of problematic or harmful alcohol consumption).

· Serve as a subject matter expert on clinical and scientific matters related to mental health and substance use disorders, digital therapeutics and artificial intelligence, and psychotherapeutic approaches to care.

· Provide cross-functional support to marketing, market access, and sales teams in order to educate internal and external stakeholders on digital therapeutics for mental health and substance use disorders.

· Partner with health care providers, health systems, advocacy groups, and professional organizations to present educational information on digital mental health, foster networking opportunities among professionals in the field, and facilitate opportunities for business development.

   Lead development and execution of real-world research and implementation science protocols.

   Lead development of medical affairs resources for deprexis and vorvida.

   Provide internal guidance and expertise to all levels of the organization, including to senior leadership.

Mallinckrodt Pharmaceuticals

Medical Science Liaison, Immune Cell Therapy

Scientific Communications Manager, Immune Cell Therapy

Bedminster, NJ

Dec 2019 – May 2020

June 2019 – Nov 2019

· Served as a medical affairs expert regarding use of extracorporeal photopheresis (ECP) in cutaneous T-cell lymphoma (CTCL), graft-versus-host disease (GvHD), solid organ transplantation, and systemic sclerosis.

· Identified, created, and managed relationships with KOLs with expertise in CTCL, acute and chronic GvHD, solid organ transplantation, and systemic sclerosis.

· Collaborated cross-functionally with global colleagues in the US, Europe, and Australia to provide scientific and medical support for commercial, clinical, and health economics projects.

   Responded to requests for medical information related to Therakos ECP.

   Collected scientific and clinical insights to inform medical strategy and tactics.

   Maintained scientific communications role and responsibilities after moving into the MSL role, which included:

o   Leading publication strategy for Therakos ECP in collaboration with the global medical affairs team.

o   Overseeing development of publications, digital scientific platforms, and field reactive slide decks.

o   Developing a cross-company patient-centered publication strategy.

Alfasigma USA

Medical Affairs Manager

Bedminster, NJ

July 2018 – May 2019

· Served as strategic and subject matter expert for four established brands across three therapeutic areas (i.e., psychiatry, neurology, and gastroenterology).

· Directed content development for scientific communications and medical education initiatives.

· Managed relationships with key opinion leaders (KOLs) across therapeutic areas, including through field-based activities as the company did not have a dedicated MSL team.

· Led medical assessment of business development and indication expansion opportunities, including development of target product profiles and contribution to forecast models.

· Led project management and maintained the project dashboard for the Medical Affairs Department.


Health and Wellness Partners

Associate Scientific Director

Associate Director, Client Services

Upper Saddle River, NJ

March 2017 – May 2018

Nov 2015 – Feb 2017

  • Provided strategic guidance to pharmaceutical, medical device, and biotechnology companies during the pre-launch, launch, and post-launch phases of product development and commercialization.
  • Developed a number of promotional medical education and scientific communication deliverables, including peer-reviewed publications, congress posters, promotional speaker decks, proactive and reactive field medical decks, and global value dossiers.
  • Led behavior change and impact metrics reporting across program types.
  • Conducted independent research to uncover clinical and educational needs in various therapeutic areas.
  • Supported SOW development and budget management.


  • American Psychological Association (APA)
  • American Public Health Association (APHA)
  • International Society of Medical Publications Professionals (ISMPP)


Graziose MM, Downs SM, O’Brien Q, Fanzo J. Systematic review of the design, implementation and effectiveness of mass media and nutrition education interventions for infant and young child feeding. Public Health Nutr. 2018;21(2):273-287.


Messina AJ, O’Brien QE, Andrianov V, Moss KR, Vidal-Fisher L. Under Reporting of Patient Reported

Outcomes (PROs) in Myeloproliferative Neoplasm (MPN) Clinical Trials. Poster presented at: 61st Annual Meeting of the American Society of Hematology; December 2019; Orlando, FL.

O’Brien QE, Lotrecchiano GR. Applying Team Science Principles to Biomedical Publications Teams: Understanding Team Effectiveness. Poster presented at: 10th Annual International Science of Team Science Conference; May 2019; Lansing, MI.

O’Brien QE, Scully J, Hegarty J. Understanding primary care providers’ and general neurologists’ interest in and need for education on Alzheimer’s Disease management. Poster presented at: 46th North American Primary Care Research Group (NAPCRG) Annual Meeting; November 2018; Chicago, IL.

Mattingly G, Jain R, O’Brien QE, Hegarty J. Investigation of Clinical Practice Challenges in the Management of ADHD. Poster presented at: American Professional Society of ADHD and Related Disorders; January 2018; Washington, DC.

O’Brien QE, Scully J, Rappa E, Smith PK, Hegarty J. Defining the Need for Better Tools and Education on Tacrolimus Intrapatient Variability to Improve Outcomes for Transplant Patients. Poster presented at: American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting; December 2017; Orlando, FL.

Jain R, Mattingly G, Pikalov A, O’Brien QE, Scully J, Smith L, Sender D, O’Brien K, Hegarty J. Unmet Needs in the Treatment of Pediatric and Adult ADHD. Poster presented at: Psych Congress; September 2017; New Orleans, LA.

O’Brien QE, Smith PK, Sender D, Hegarty J. Practice Perspectives on Telepsychiatry Use. Poster presented at: U.S. Psychiatric and Mental Health Congress; October 2016; San Antonio, TX.

O’Brien QE, Downs S, Graziose M, Fanzo J. Assessing Nutrition Knowledge Gaps and IYCF Practices of Mothers in Rural Senegal: A Formative Assessment for Nutrition Education. Oral presentation at: Mailman School of Public Health Student Research Diversity Day; May 2015; New York, NY.

Depression, Problematic Drinking, Opioid Use Disorder, and the Role of Digital Therapeutics – Overview
© EAPA Lone Star
Powered by Wild Apricot. Try our all-in-one platform for easy membership management